Nidufexor
Chemical compound
Identifiers | |
---|---|
| |
CAS Number |
|
PubChem CID |
|
ChemSpider |
|
UNII |
|
ChEMBL |
|
Chemical and physical data | |
Formula | C27H22ClN3O4 |
Molar mass | 487.94 g·mol−1 |
3D model (JSmol) |
|
| |
InChI
|
Nidufexor (LMB-763) is a drug which acts as a partial agonist of the farnesoid X receptor (FXR). It has reached Phase II clinical trials for the treatment of diabetic nephropathy and nonalcoholic steatohepatitis.[1][2]
See also
- GSK-4112
- SR9009
- SR9011
References
- ^ Chianelli D, Rucker PV, Roland J, Tully DC, Nelson J, Liu X, et al. (April 2020). "Nidufexor (LMB763), a Novel FXR Modulator for the Treatment of Nonalcoholic Steatohepatitis". Journal of Medicinal Chemistry. 63 (8): 3868–3880. doi:10.1021/acs.jmedchem.9b01621. PMID 31940200.
- ^ Fiorucci S, Biagioli M, Sepe V, Zampella A, Distrutti E (June 2020). "Bile acid modulators for the treatment of nonalcoholic steatohepatitis (NASH)". Expert Opinion on Investigational Drugs. 29 (6): 623–632. doi:10.1080/13543784.2020.1763302. PMID 32552182. S2CID 219911969.
- v
- t
- e
FXRTooltip Farnesoid X receptor and LXRTooltip liver X receptor modulators
- Agonists: Bile acids
- Cafestol
- Chenodeoxycholic acid
- Cilofexor
- Fexaramine
- GW-4064
- Ivermectin
- Nidufexor
- Obeticholic acid
- Tropifexor
- Antagonists: Guggulsterone
- Agonists: 22R-Hydroxycholesterol
- 24S-Hydroxycholesterol
- 27-Hydroxycholesterol
- Abequolixron
- Cholestenoic acid
- DMHCA
- GW-3965
- Hypocholamide
- T-0901317
- Antagonists: Efavirenz
- Larsucosterol
- See also
- Receptor/signaling modulators
This pharmacology-related article is a stub. You can help Wikipedia by expanding it. |
- v
- t
- e